Antipsychotics: Weight Gain,
Metabolism, and Management
Antipsychotic Medications - ANS Medications that can cause metabolic side effects.
Weight Gain Threshold - ANS Weight gain exceeding 5% in the first month.
Triglycerides Monitoring - ANS Elevated triglycerides after treatment initiation indicate risk.
Low-Risk Antipsychotics - ANS Includes aripiprazole, brexpiprazole, and lurasidone.
Moderate-Risk Antipsychotics - ANS Includes quetiapine, risperidone, and paliperidone.
High-Risk Antipsychotics - ANS Includes clozapine and olanzapine, linked to weight gain.
H1 Receptor Antagonism - ANS Interferes with gut satiety signals, increasing intake.
5-HT2C Receptor Antagonism - ANS Associated with increased food intake and weight gain.
Metabolic Monitoring Protocol - ANS Routine checks at 4, 8, 12 weeks, then quarterly.
Behavioral Interventions - ANS Encouragement of healthy diet and regular exercise.
Olanzapine/Samidorphan - ANS Preferred to reduce weight gain compared to olanzapine.
Metformin - ANS Improves weight, glucose, triglycerides; starts at 500 mg.
Naltrexone + Bupropion - ANS Effective for obesity management in patients.
Liraglutide - ANS Weight loss agent requiring injections, expensive.
Topiramate - ANS Prevents weight gain but may impair cognition.
Switching Antipsychotics - ANS Switching to aripiprazole or ziprasidone may help.
Plasma Levels - ANS Best predictors of antipsychotic response and adherence.
Relapse Rates - ANS Higher in patients discontinuing antipsychotic treatment.
, Therapeutic D2 Blockade - ANS Achieved with 60-80% D2 receptor occupancy.
Aripiprazole Plasma Levels - ANS Optimal range is 150-500 ng/mL.
Clozapine Plasma Levels - ANS Recommended range is 350-700 ng/mL.
Haloperidol Plasma Levels - ANS Therapeutic range is 3-20 ng/mL.
Olanzapine Plasma Levels - ANS Recommended levels are 20-80 ng/mL.
Genetic Polymorphisms - ANS Affect metabolism of antipsychotics via CYP450 enzymes.
Smoking Impact - ANS Cigarette smoke lowers plasma levels of clozapine.
Plasma Level Monitoring - ANS Should be done during clinical stability.
Treatment Adjustments - ANS Based on clinical response and plasma levels.
Active Metabolites - ANS Contribute to clinical effects of antipsychotics.
First-Generation Antipsychotics - ANS Potent D2 blockers, effective for positive symptoms.
Second-Generation Antipsychotics - ANS Treat both positive and negative symptoms
effectively.
Weight - ANS A measure of body mass, typically in kilograms or pounds.
BMI - ANS Body Mass Index, a measure of body fat based on height and weight.
Waist Circumference - ANS A measurement around the waist, used to assess abdominal fat.
Blood Pressure - ANS The pressure of circulating blood on the walls of blood vessels.
Fasting Plasma Glucose - ANS A test measuring blood sugar levels after fasting for at least 8
hours.
HbA1C - ANS A blood test that indicates average blood sugar levels over the past 2-3 months.
Lipid Profile - ANS A blood test measuring cholesterol and triglycerides levels.
Akathisia - ANS Motor restlessness, difficulty staying still.
Akinesia - ANS Difficulty initiating movement, subjective lack of motivation.
Metabolism, and Management
Antipsychotic Medications - ANS Medications that can cause metabolic side effects.
Weight Gain Threshold - ANS Weight gain exceeding 5% in the first month.
Triglycerides Monitoring - ANS Elevated triglycerides after treatment initiation indicate risk.
Low-Risk Antipsychotics - ANS Includes aripiprazole, brexpiprazole, and lurasidone.
Moderate-Risk Antipsychotics - ANS Includes quetiapine, risperidone, and paliperidone.
High-Risk Antipsychotics - ANS Includes clozapine and olanzapine, linked to weight gain.
H1 Receptor Antagonism - ANS Interferes with gut satiety signals, increasing intake.
5-HT2C Receptor Antagonism - ANS Associated with increased food intake and weight gain.
Metabolic Monitoring Protocol - ANS Routine checks at 4, 8, 12 weeks, then quarterly.
Behavioral Interventions - ANS Encouragement of healthy diet and regular exercise.
Olanzapine/Samidorphan - ANS Preferred to reduce weight gain compared to olanzapine.
Metformin - ANS Improves weight, glucose, triglycerides; starts at 500 mg.
Naltrexone + Bupropion - ANS Effective for obesity management in patients.
Liraglutide - ANS Weight loss agent requiring injections, expensive.
Topiramate - ANS Prevents weight gain but may impair cognition.
Switching Antipsychotics - ANS Switching to aripiprazole or ziprasidone may help.
Plasma Levels - ANS Best predictors of antipsychotic response and adherence.
Relapse Rates - ANS Higher in patients discontinuing antipsychotic treatment.
, Therapeutic D2 Blockade - ANS Achieved with 60-80% D2 receptor occupancy.
Aripiprazole Plasma Levels - ANS Optimal range is 150-500 ng/mL.
Clozapine Plasma Levels - ANS Recommended range is 350-700 ng/mL.
Haloperidol Plasma Levels - ANS Therapeutic range is 3-20 ng/mL.
Olanzapine Plasma Levels - ANS Recommended levels are 20-80 ng/mL.
Genetic Polymorphisms - ANS Affect metabolism of antipsychotics via CYP450 enzymes.
Smoking Impact - ANS Cigarette smoke lowers plasma levels of clozapine.
Plasma Level Monitoring - ANS Should be done during clinical stability.
Treatment Adjustments - ANS Based on clinical response and plasma levels.
Active Metabolites - ANS Contribute to clinical effects of antipsychotics.
First-Generation Antipsychotics - ANS Potent D2 blockers, effective for positive symptoms.
Second-Generation Antipsychotics - ANS Treat both positive and negative symptoms
effectively.
Weight - ANS A measure of body mass, typically in kilograms or pounds.
BMI - ANS Body Mass Index, a measure of body fat based on height and weight.
Waist Circumference - ANS A measurement around the waist, used to assess abdominal fat.
Blood Pressure - ANS The pressure of circulating blood on the walls of blood vessels.
Fasting Plasma Glucose - ANS A test measuring blood sugar levels after fasting for at least 8
hours.
HbA1C - ANS A blood test that indicates average blood sugar levels over the past 2-3 months.
Lipid Profile - ANS A blood test measuring cholesterol and triglycerides levels.
Akathisia - ANS Motor restlessness, difficulty staying still.
Akinesia - ANS Difficulty initiating movement, subjective lack of motivation.
